Emergency Medicine

HIV / AIDS

Medical News

Primary Care

Surgery

Home » Fibromyalgia, Medical News

Jazz Pharmaceuticals And UCB Announce Second Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia Meets Primary Endpoints

Submitted by MedicalReplies on Thursday, 25 June 2009No Comment

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the second of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia.

The rest is here:
Jazz Pharmaceuticals And UCB Announce Second Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia Meets Primary Endpoints

You may also like:

Leave your response!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.

*
To prove you're a person (not a spam script), type the security word shown in the picture.
Anti-spam image